High-Throughput Viral Vector Process Development Market
完整報告名稱與涵蓋範圍
High-Throughput Viral Vector Process Development Market Size, Share & Trends Analysis Report, By Offering (Automated Microbioreactor and Screening Systems, Analytical and Characterization Platforms, Process Development Software and Design-of-Experiment Tools, Contract Process Development Services), By Vector Type (Adeno-Associated Virus, Lentivirus, Adenovirus and Other Vectors), By Development Stage (Upstream Process Development, Downstream Process Development, Formulation and Stability Development), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The high-throughput viral vector process development market covers the automated screening systems, analytical platforms, software and contract services used to design and optimise upstream, downstream and formulation processes for adeno-associated, lentiviral and other viral vectors before GMP manufacturing. GMP vector production, research-grade vector supply and plasmid manufacturing are excluded.
Process development has become the decisive lever in gene therapy economics because vector yields, full-capsid ratios and recovery through purification determine cost per dose and the feasibility of systemic indications. Developers and CDMOs are replacing manual shake-flask work with parallel microbioreactors, automated liquid handling and design-of-experiment software that can screen dozens of media, transfection and chromatography conditions at once, supported by rapid analytics such as mass photometry, capillary electrophoresis and digital PCR that quantify titer and quality within hours. Regulatory expectations for well-characterised processes, the trend toward producer cell lines and the need to compress timelines for rare-disease programs sustain investment.
North America and Europe host most developers and tool vendors, with China and South Korea building capability alongside domestic gene therapy pipelines. Competition involves bioprocess equipment leaders, analytical instrument companies and CDMOs offering process development as a front-end service.
The InsightAce study supplies US$ forecasts for all offering, vector type, development stage and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global High-Throughput Viral Vector Process Development Market Snapshot
Chapter 4. Global High-Throughput Viral Vector Process Development Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Offering Estimates & Trend Analysis
5.1. Offering & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Offering:
5.2.1. Automated Microbioreactor and Screening Systems
5.2.2. Analytical and Characterization Platforms
5.2.3. Process Development Software and Design-of-Experiment Tools
5.2.4. Contract Process Development Services
Chapter 6. Market Segmentation 2: By Vector Type Estimates & Trend Analysis
6.1. Vector Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Vector Type:
6.2.1. Adeno-Associated Virus
6.2.2. Lentivirus
6.2.3. Adenovirus and Other Vectors
Chapter 7. Market Segmentation 3: By Development Stage Estimates & Trend Analysis
7.1. Development Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
7.2.1. Upstream Process Development
7.2.2. Downstream Process Development
7.2.3. Formulation and Stability Development
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Gene Therapy Developers
8.2.2. CDMOs
8.2.3. Academic and Translational Centers
Chapter 9. High-Throughput Viral Vector Process Development Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Sartorius AG
11.2. Cytiva (Danaher)
11.3. Thermo Fisher Scientific Inc.
11.4. Merck KGaA (MilliporeSigma)
11.5. Beckman Coulter Life Sciences (Danaher)
11.6. Lonza Group AG
11.7. Charles River Laboratories International, Inc.
11.8. Oxford Biomedica plc
11.9. Genezen Laboratories, Inc.
11.10. Andelyn Biosciences, Inc.
11.11. Bio-Rad Laboratories, Inc.
11.12. Agilent Technologies, Inc.
11.13. Repligen Corporation
11.14. Cell and Gene Therapy Catapult
11.15. Refeyn Ltd.
圖表清單 List of Tables & Figures
Table 1. Global High-Throughput Viral Vector Process Development Revenue Forecast by Offering, 2026-2035 (US$ Mn)
Figure 1. Global High-Throughput Viral Vector Process Development Market Snapshot, 2026 & 2035
Table 2. Global High-Throughput Viral Vector Process Development Revenue Forecast by Vector Type, 2026-2035 (US$ Mn)
Figure 2. Global High-Throughput Viral Vector Process Development Market Share by Vector Type, 2026 & 2035
Table 3. Global High-Throughput Viral Vector Process Development Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 3. High-Throughput Process Development Workflow from Screening to Scale-Up
Table 4. Global High-Throughput Viral Vector Process Development Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Impact of Yield and Full-Capsid Improvements on Vector Cost per Dose
Table 5. North America High-Throughput Viral Vector Process Development Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific High-Throughput Viral Vector Process Development Growth Opportunity Analysis
Table 6. Europe High-Throughput Viral Vector Process Development Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Analytical Platform Adoption for Rapid Titer and Quality Measurement
Table 7. Asia Pacific High-Throughput Viral Vector Process Development Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key High-Throughput Viral Vector Process Development Market Participants
Table 8. Latin America and Middle East & Africa High-Throughput Viral Vector Process Development Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們